The facility is designed to serve customers with process & analytical development and small-scale manufacturing of antibodies and other recombinant proteins for preclinical and early-phase clinical requirements. The process and analytical development laboratories are now operational while the commissioning of manufacturing capacity will be completed later in 2024.

The state-of-the-art facility is equipped with top-tier equipment and staff, enhancing its current discovery capabilities focused on complex proteins. This addition expands its end-to-end service offering, delivering solutions from discovery to large-scale commercial manufacturing. The new Genome Valley facility will provide robust and compliant cell lines, process development solutions, and analytical methods, supporting customers’ rapid clinical development progression. This initiative is part of Aurigene’s strategy to support growth in both small molecule and biologics spaces, as shown by recent AI/ML-led drug discovery and a collaboration with Vipergen, a DNA-encoded library technologies service provider.

Akhil Ravi, CEO, Aurigene, commented, “The journey started a year back when we decided to invest in creating the facility. It is great to see the facility operational and the addition of this capacity and capabilities shows our firm commitment to the continued expansion of our biologics business, building on 25 years of proven experience. The state-of-the-art facility will enable us to service our global customers efficiently and support in the development of innovative medicine.”

Roger Lias, Global Commercial Head – Biologics, Aurigene, added, “There are very few global CDMOs that can truly support customers “end-to-end” from discovery services to large scale commercial manufacture of both Drug Substance and Drug Product. Our new facility further strengthens Aurigene’s capabilities and builds on our technical excellence, demonstrated global compliance and state-of-the-art facilities as companies from start-up biotechs to global multinationals continue to strengthen their supply chains and seek economically viable support for both their development portfolios and marketed products.”